Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

Clinical trial NCT00644878 · TERMINATED

Trial details

NCT number: NCT00644878
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myelogenous Leukemia - Chronic Phase

Start date: 2008-10-01
Primary completion: 2012-03-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.